ICOS Antikörper

Produktnummer ABIN1176983

Der Ratte Monoklonal Anti-ICOS-Antikörper wurde für FACS und BR validiert. Er ist geeignet, ICOS in Proben von Maus zu detektieren. Es sind 9+ Publikationen verfügbar.

Kurzübersicht für ICOS Antikörper (ABIN1176983)

Target: ICOS (Inducible T-Cell Co-Stimulator (ICOS))

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser ICOS Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Blocking Reagent (BR)

Klon: 7E-17G9

Produktdetails anti-ICOS Antikörper

Marke: BD Pharmingen™

Aufreinigung: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: Endotoxin level is ≤ 0.01 EU/μg (≤ 0.001 ng/μg) of protein as determined by the LAL assay.

Immunogen: Mouse Icos cDNA and ICOS hexahistidine fusion protein

Isotyp: IgG2b kappa

Anwendungsinformationen

Applikationshinweise: Since this antigen is expressed at only moderate density on activated T lymphocytes, it may be desirable to amplify the staining by using a biotinylated second-step antibody with a bright third-step reagent, such as Streptavidin-PE (Cat. No. 554061). Furthermore, we have found that polyclonal goat anti-rat Ig is weakly reactive with this rat IgG2b mAb, so we recommend the use of biotinylated anti-rat IgG2b mAb RG7/11.1 (Cat. No. 553898) as the second step.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1.0 mg/mL

Buffer: No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2μm sterile filtered.

Konservierungsmittel: Azide free

Lagerung: 4 °C

Informationen zur Lagerung: Store undiluted at 4°C. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

Referenzen für anti-ICOS Antikörper (ABIN1176983)

Buonfiglio, Bragardo, Redoglia, Vaschetto, Bottarel, Bonissoni, Bensi, Mezzatesta, Janeway Jr, Dianzani: "The T cell activation molecule H4 and the CD28-like molecule ICOS are identical." in: European journal of immunology, Vol. 30, Issue 12, pp. 3463-7, (2001) (PubMed).

Chambers: "The expanding world of co-stimulation: the two-signal model revisited." in: Trends in immunology, Vol. 22, Issue 4, pp. 217-23, (2001) (PubMed).

Dong, Temann, Flavell: "Cutting edge: critical role of inducible costimulator in germinal center reactions." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 166, Issue 6, pp. 3659-62, (2001) (PubMed).

Gonzalo, Delaney, Corcoran, Goodearl, Gutierrez-Ramos, Coyle: "Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 166, Issue 1, pp. 1-5, (2001) (PubMed).

Schwartz: "Immunology. It takes more than two to tango." in: Nature, Vol. 409, Issue 6816, pp. 31-2, (2001) (PubMed).

Sperling, Bluestone: "ICOS costimulation: It's not just for TH2 cells anymore." in: Nature immunology, Vol. 2, Issue 7, pp. 573-4, (2001) (PubMed).

Wallin, Liang, Bakardjiev, Sha: "Enhancement of CD8+ T cell responses by ICOS/B7h costimulation." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 167, Issue 1, pp. 132-9, (2001) (PubMed).

Mages, Hutloff, Heuck, Büchner, Himmelbauer, Oliveri, Kroczek: "Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand." in: European journal of immunology, Vol. 30, Issue 4, pp. 1040-7, (2000) (PubMed).

McAdam, Chang, Lumelsky, Greenfield, Boussiotis, Duke-Cohan, Chernova, Malenkovich, Jabs, Kuchroo, Ling, Collins, Sharpe, Freeman: "Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 165, Issue 9, pp. 5035-40, (2000) (PubMed).

Details zu ICOS

Target: ICOS (Inducible T-Cell Co-Stimulator (ICOS))

Andere Bezeichnung: CD278

Hintergrund: The 7E.17G9 antibody reacts with CD278, the Inducible Costimulatory molecule (ICOS), a 47-57 kDa homodimeric glycoprotein of the CD28 family of costimulatory molecules. ICOS is expressed on subpopulations of CD4-CD8- and CD4+CD8- (but not CD4-CD8+ or CD4+CD8+) thymocytes, on some T-cell lines, and on small numbers of peripheral leukocytes. It is upregulated on T lymphocytes following activation via the T-cell receptor. The T-cell activation marker H4 is the same molecule as ICOS. ICOS is a costimulatory receptor, and its ligand on antigen-presenting cells has been called B7RP-1, GL50, B7h, B7-H2, or LICOS. There is considerable evidence that the interaction of ICOS with its ligand is involved in the regulation of many, but not all, T-cell-mediated immune responses.
Synonyms: ICOS

Pathways: Cancer Immune Checkpoints